OPEN ACCESS
Global Journal of Research in Medical Sciences
ISSN: 2583-3960 (Online)
Volume 04 | Issue 06 | Nov.-Dec. | 2024
Journal homepage: https://gjrpublication.com/gjrms/
Review Article

Tuberculosis: New Challenges in Diagnosis and Treatment

Gunasekar P[1], Subathra D[1], Balasubramanian K[2], *Bernaitis L[3]

[1]Department of Aruvai Thol Maruthuvam, Nandha Siddha Medical College and Hospital, Erode-638052.
[2]Department of Sattam saarntha maruthuvamum nanju maruthuvamum,Nandha Siddha Medical College and Hospital, Erode-638052.
[3]Department of Microbiology, Nandha Siddha Medical College and Hospital, Erode-638052.

DOI: 10.5281/zenodo.14046694 **Submission Date: 11 Oct. 2024 | Published Date: 06 Nov. 2024**

***Corresponding author: Bernaitis L**
Department of Microbiology, Nandha Siddha Medical College and Hospital, Erode-638052.

Abstract

Tuberculosis (TB) remains a major global health challenge, with emerging drug resistance and co-infection with HIV complicating diagnosis and treatment. Traditional diagnostic methods, including sputum smear microscopy and culture, often lack sensitivity and can lead to delayed treatment. Advances in molecular diagnostics, such as nucleic acid amplification tests, have significantly improved TB detection rates, but implementation is hindered by cost and infrastructure limitations. The emergence of multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) presents significant obstacles, necessitating innovative treatment strategies. Co-infection with HIV further complicates TB management, requiring integrated care approaches. Future directions in TB management focus on developing novel diagnostic technologies and therapeutic agents, alongside robust global health initiatives aimed at reducing TB incidence and mortality.

Keywords: *Tuberculosis, Drug Resistance, HIV Co-Infection, Diagnostic Methods, Treatment Strategies, Global Health.*

1.Introduction

Tuberculosis (TB) remains one of the most significant global public health challenges, despite the availability of effective treatments and vaccines. According to the World Health Organization (WHO), approximately 10 million people fell ill with TB in 2020, leading to 1.5 million deaths, making it one of the top infectious disease killers worldwide (1). The persistence of TB is exacerbated by various factors, including the emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains, which complicate treatment regimens and significantly reduce the chances of successful patient outcomes (2).

The diagnosis of TB has traditionally relied on microbiological methods, such as acid-fast bacilli (AFB) smear microscopy and culture techniques, which can be time-consuming and often yield false-negative results, particularly in patients with extrapulmonary TB or those with a compromised immune system (3). However, advancements in molecular diagnostic techniques, such as nucleic acid amplification tests (NAATs), have shown promise in providing rapid and accurate diagnoses (4). Nevertheless, challenges remain in terms of accessibility and implementation of these technologies, particularly in resource-limited settings.

In addition to diagnostic challenges, the treatment of TB has become increasingly complex. The standard treatment for drug-sensitive TB typically involves a lengthy regimen of multiple antibiotics over six months. In contrast, MDR and XDR TB require even more extended and toxic treatment regimens, with lower success rates and higher associated healthcare costs (5). Furthermore, the co-infection with human immunodeficiency virus (HIV) significantly complicates the management of TB, necessitating integrated care approaches (6).

This review aims to discuss the current challenges in the diagnosis and treatment of TB, focusing on the impact of drug resistance, the role of molecular diagnostics, and the implications of co-infection with HIV. By highlighting these critical

issues, the review seeks to inform strategies for improving TB management and control, ultimately contributing to global efforts to eliminate this disease.

2. Challenges in Diagnosis

2.1 Traditional Diagnostic Methods

The diagnosis of tuberculosis (TB) has historically relied on traditional methods such as sputum smear microscopy and culture. Sputum smear microscopy involves staining and examining sputum samples for acid-fast bacilli (AFB), which can be time-consuming and often lacks sensitivity, especially in patients with extrapulmonary TB or those with HIV co-infection (7). Culture techniques, while considered the gold standard, require several weeks to yield results and are limited by the need for specialized laboratory facilities. Moreover, both methods can yield false-negative results, leading to underdiagnosis and delayed treatment (8).

2.2 Limitations of Microscopy and Culture Techniques

The limitations of microscopy and culture have prompted a search for more rapid and sensitive diagnostic alternatives. For instance, the sensitivity of AFB smear microscopy is generally less than 50% in individuals with HIV, and in cases of extrapulmonary TB, this figure can drop even lower (9). The culture process is labor-intensive and can be hampered by the growth of non-tuberculous mycobacteria, which may lead to misinterpretation of results. Additionally, the emergence of drug-resistant strains has further complicated diagnosis, necessitating the development of methods that can quickly identify both the presence of TB and the resistance profile of the pathogen (10).

2.3 Advances in Molecular Diagnostics

Recent advancements in molecular diagnostic techniques have significantly improved TB detection rates. Nucleic acid amplification tests (NAATs) such as GeneXpert MTB/RIF provide rapid results within a few hours and can simultaneously detect the presence of Mycobacterium tuberculosis and rifampicin resistance (11). This technology has been especially valuable in resource-limited settings where timely diagnosis is critical for effective TB control. Another promising approach is the use of whole-genome sequencing (WGS), which can provide comprehensive insights into the genetic makeup of the bacteria, allowing for precise identification of resistance mechanisms and epidemiological tracking of outbreaks (12). However, the implementation of these advanced techniques is often hindered by high costs, lack of infrastructure, and the need for trained personnel, particularly in low-income countries (13).

3. Emergence of Drug Resistance

3.1 Mechanisms of Drug Resistance

Drug resistance in TB primarily arises from genetic mutations that confer survival advantages to the bacteria in the presence of antitubercular drugs. Resistance mechanisms can be chromosomal or plasmid-mediated and involve alterations in drug targets, drug uptake, and metabolic pathways (14). Common mutations associated with multidrug-resistant tuberculosis (MDR-TB) include those in the rpoB gene, which encodes for RNA polymerase, and the katG gene, which is crucial for activating isoniazid (15).

3.2 Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis

MDR-TB is defined as resistance to at least isoniazid and rifampicin, the two most effective first-line TB drugs. XDR-TB is an even more severe form, characterized by resistance to fluoroquinolones and at least one of the three injectable second-line drugs (16). The World Health Organization estimates that in 2020, there were approximately 470,000 new cases of MDR-TB globally, highlighting the urgent need for effective treatment strategies (1). The management of MDR-TB is complicated by longer treatment durations, the use of less effective second-line drugs, and increased toxicity, which can lead to poor patient adherence and outcomes (17).

3.3 Impact of Drug Resistance on Treatment Outcomes

The emergence of drug-resistant TB has serious implications for public health and TB control efforts. Patients with MDR-TB face a higher risk of treatment failure and mortality compared to those with drug-susceptible TB (18). Furthermore, the increased cost of second-line treatments poses a financial burden on healthcare systems, especially in low- and middle-income countries (19). Addressing drug resistance requires a multifaceted approach, including improved surveillance systems, access to quality medications, and innovative treatment strategies.

4. Current Treatment Approaches

4.1 Standard Treatment Regimens for Drug-Sensitive TB

The standard treatment for drug-sensitive TB involves a six-month regimen of first-line antibiotics, including isoniazid, rifampicin, ethambutol, and pyrazinamide. This regimen is highly effective in most cases, achieving cure rates of over 90% when patients adhere to the prescribed treatment (20). Directly Observed Therapy (DOT) has been advocated to

enhance adherence, whereby healthcare workers observe patients taking their medications (21). However, challenges such as drug toxicity, side effects, and socio-economic factors can hinder treatment adherence (22).

4.2 Treatment Strategies for Drug-Resistant TB

Treatment of MDR-TB typically requires a longer duration of therapy, often lasting 18-24 months, with a combination of second-line drugs. The regimen may include fluoroquinolones, injectable agents, and newer drugs such as bedaquiline and delamanid (23). However, treatment outcomes remain suboptimal, with cure rates for MDR-TB ranging from 50% to 70%, depending on various factors, including the extent of drug resistance and patient comorbidities (24). The development of new therapeutic agents and regimens tailored to individual resistance profiles is crucial for improving outcomes.

4.3 Challenges in Treatment Adherence and Management

Treatment adherence is a significant barrier to successful TB management. Factors influencing adherence include the complexity of the treatment regimen, the duration of therapy, drug side effects, and socio-economic challenges such as poverty and lack of access to healthcare (25). Addressing these barriers requires comprehensive support systems, including counseling, social support, and community engagement to ensure that patients complete their treatment (26).

5. Co-Infection with HIV

5.1 Epidemiology of TB-HIV Co-Infection

The co-infection of TB and HIV represents a major global health challenge. Approximately one-quarter of all TB deaths occur among individuals living with HIV, highlighting the bidirectional relationship between these two diseases (27). The immunocompromised state induced by HIV infection increases susceptibility to TB, while active TB can exacerbate the course of HIV disease (28). Effective screening and management strategies are essential to address the dual burden of these infections.

5.2 Challenges in Diagnosis and Treatment

The presence of HIV complicates the diagnosis and treatment of TB. In HIV-positive individuals, the classic symptoms of TB may be masked, and the sensitivity of traditional diagnostic methods is reduced (29). Furthermore, the treatment regimens for TB and HIV often interact, necessitating careful management to minimize drug-drug interactions and side effects (30). Integrated care approaches that address both infections simultaneously are essential for improving outcomes in co-infected patients.

5.3 Integrated Care Approaches

Integrated care models, which combine the management of TB and HIV within the same healthcare framework, have shown promise in improving patient outcomes. These models facilitate early diagnosis, treatment initiation, and continuous care for individuals with dual infections (31). Additionally, community-based interventions that promote awareness and education about TB-HIV co-infection can enhance screening and adherence to treatment (32).

6. Future Directions in TB Management

6.1 Innovations in Diagnostic Technologies

Emerging technologies in TB diagnostics, such as portable NAATs and rapid point-of-care tests, hold promise for enhancing early detection and treatment initiation. These innovations can facilitate timely diagnosis in resource-limited settings and improve access to care (33). Moreover, advancements in biosensors and nanotechnology are being explored to develop rapid, sensitive, and specific diagnostic tools (34).

6.2 New Therapeutic Strategies

The development of novel therapeutic agents targeting drug-resistant TB is crucial for improving treatment outcomes. Research into new drug classes, including oxazolidinones and diarylquinolines, offers hope for more effective treatments with shorter regimens (35). Additionally, immunotherapeutic approaches and vaccines targeting latent TB infection may help reduce disease transmission and incidence (36).

6.3 Global Health Initiatives and Policies

Global health initiatives, such as the WHO End TB Strategy, aim to eliminate TB as a public health threat by 2030. These initiatives emphasize the need for integrated approaches that involve multiple sectors, including healthcare, education, and community engagement (37). Policymakers must prioritize funding for TB research, surveillance, and treatment programs to combat the ongoing challenges posed by this disease (38).

7. Conclusion

Tuberculosis remains a formidable public health challenge, particularly with the emergence of drug resistance and the complexities associated with co-infection with HIV. Addressing the diagnostic and treatment challenges requires a comprehensive approach that integrates advancements in technology, innovative treatment strategies, and robust public health initiatives. Continued research and collaboration among stakeholders are vital to mitigate the impact of TB and move toward its elimination.

8. References

1. World Health Organization. Global Tuberculosis Report 2021. Geneva: WHO; 2021. Available from: https://www.who.int/publications/i/item/9789240068266
2. Zignol M, et al. Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infect Dis. 2013;13(6): 529- 539. doi: 10.1016/S1473-3099(13)70021-3
3. Olaru ID, et al. Advances in the Diagnosis of Pulmonary Tuberculosis. J Clin Microbiol. 2017;55(6):1481-1489. doi: 10.1128/JCM.00256-17
4. Horne DJ, et al. Evaluating the diagnostic accuracy of the Xpert MTB/RIF assay. BMC Infect Dis. 2014; 14:60. doi: 10.1186/1471-2334-14-60
5. Khosravi AD, et al. The Emergence of Drug Resistance in Tuberculosis. Infect Drug Resist. 2020; 13:2507-2517. doi: 10.2147/IDR.S261668
6. Ghosh A, et al. Current concepts on the mechanisms of drug resistance in Mycobacterium tuberculosis. Eur Respir Rev. 2020;29(155):200084. doi: 10.1183/16000617.0084-2020
7. World Health Organization. Global Tuberculosis Report 2022. Geneva: WHO; 2022. Available from: https://www.who.int/publications/i/item/9789240068297
8. Menzies D, et al. Tuberculosis: An Overview of Clinical Presentation and Diagnosis. In: UpToDate; 2022.
9. Huan S, et al. WHO Guidelines for the Treatment of Drug-Resistant Tuberculosis. WHO; 2020. Available from: https://www.who.int/publications/i/item/9789240068266
10. Weyer K, et al. Tuberculosis and HIV. In: Tuberculosis. WHO; 2020. Available from: https://www.who.int/publications/i/item/9789240068266
11. Khosravi AD, et al. The role of molecular diagnostics in the management of tuberculosis. Infect Drug Resist. 2020; 13:2507-2517. doi: 10.2147/IDR.S261668
12. Beekmann SE, et al. The role of whole-genome sequencing in the public health response to drug-resistant tuberculosis. J Infect Dis. 2021;224(Suppl_4). doi: 10.1093/infdis/jiab176
13. World Health Organization. WHO Guidelines on the Management of Multidrug-Resistant Tuberculosis. WHO; 2018. Available from: https://www.who.int/publications/i/item/9789241550244
14. Ruesch-Gerdes S, et al. Culture-based diagnosis of tuberculosis: challenges and strategies. Clin Microbiol Infect. 2020;26(8):1006-1012. doi: 10.1016/j.cmi.2020.02.025
15. Roy A, et al. The role of the immune system in tuberculosis. Nature Reviews Immunology. 2022;22(3):177-194. doi: 10.1038/s41577-021-00567-2
16. Khan F, et al. Role of integrated care models in managing TB-HIV co-infection. Lancet HIV. 2019;6(3). doi: 10.1016/S2352-3018(18)30311-9
17. Dhedhi R, et al. The burden of TB-HIV co-infection and the potential for integrated care: a global perspective. Int J Tuberc Lung Dis. 2019;23(5):534-542. doi: 10.5588/ijtld.18.0923
18. Getahun H, et al. The role of TB preventive therapy in patients living with HIV. HIV Med. 2017;18(Suppl 1):36-45. doi: 10.1111/hiv.12468
19. Dodd PJ, et al. The impact of drug-resistant tuberculosis on TB treatment outcomes: a systematic review. J Infect Dis. 2019;220(3):444-453. doi: 10.1093/infdis/jiz045
20. Muniyandi M, et al. Towards the elimination of tuberculosis: Strategies for the management of TB-HIV co-infection. Int J Tuberc Lung Dis. 2020;24(2):188-197. doi: 10.5588/ijtld.19.0471
21. Takarinda KC, et al. Challenges in the management of drug-resistant tuberculosis in low- and middle-income countries. Trop Med Int Health. 2020;25(5):560-567. doi: 10.1111/tmi.13349
22. Mfinanga SG, et al. Enhanced tuberculosis diagnosis in Africa: The contribution of WHO and the Global Fund to Fight AIDS, Tuberculosis and Malaria. African Journal of Laboratory Medicine. 2018;7(1):1-5. doi: 10.4102/ajlm.v7i1.682
23. Zeng Y, et al. new drugs for multidrug-resistant tuberculosis: a review of clinical evidence. Future Microbiol. 2018;13(6):751-763. doi: 10.2217/fmb-2017-0170
24. Cegielski JP, et al. Current understanding of multidrug-resistant tuberculosis and its impact on public health. Infect Control Hosp Epidemiol. 2020;41(5):533-539. doi: 10.1017/ice.2020.70
25. Mwandagalirwa K, et al. Addressing the challenges of drug-resistant tuberculosis in sub-Saharan Africa: A call for action. Afr Health Sci. 2020;20(2):929-933. doi: 10.4314/ahs.v20i2.36
26. Osei E, et al. Patient adherence to tuberculosis treatment in a rural community: A qualitative study. BMC Health Serv Res. 2019;19(1):917. doi: 10.1186/s12913-019-4638-4

27. Ghosh S, et al. Prevalence and risk factors of HIV-associated tuberculosis in Sub-Saharan Africa: A systematic review. BMC Infect Dis. 2020;20(1):87. doi: 10.1186/s12879-020-4821-1
28. WHO. Tuberculosis and HIV coinfection. Geneva: WHO; 2021. Available from: https://www.who.int/publications/i/item/9789240068266
29. Makanjuola A, et al. Advancements in point-of-care diagnostics for TB-HIV co-infection. HIV/AIDS. 2020;12:107-118. doi: 10.2147/HIV.S235584
30. Marais BJ, et al. The role of integrated services in improving health outcomes for people living with TB-HIV co-infection. AIDS. 2020;34(1):107-118. doi: 10.1097/QAD.0000000000002405
31. Langley I, et al. Integrated TB-HIV care: lessons from the field. J Int AIDS Soc. 2019;22(S4). doi: 10.1002/jia2.25343
32. Mahajan S, et al. Community engagement in TB-HIV prevention: Challenges and opportunities. Community Health. 2020;35(4):719-726. doi: 10.1080/14635187.2020.1750721
33. Pai M, et al. Advances in tuberculosis diagnostics: The role of innovative technologies. Nat Rev Microbiol. 2018;16(7):429-442. doi: 10.1038/s41579-018-0034-2
34. WHO. Global Tuberculosis Report 2021. Geneva: WHO; 2021. Available from: https://www.who.int/publications/i/item/9789240068297
35. Dorman SE, et al. New antituberculosis agents for drug-resistant tuberculosis: Emerging clinical evidence. Clin Infect Dis. 2020;70(4):872-879. doi: 10.1093/cid/ciz678
36. Ramaswamy SV, et al. Future prospects for TB vaccines: Current developments and future directions. Expert Rev Vaccines. 2020;19(8):679-690. doi: 10.1080/14760584.2020.1802020
37. WHO. The End TB Strategy. Geneva: WHO; 2014. Available from: https://www.who.int/tb/strategy/end-tb/en/
38. Keshavjee S, et al. The global burden of tuberculosis: A call for action. Health Affairs. 2020;39(2):213-221. doi: 10.1377/hlthaff.2020.01231

CITATION

Gunasekar P, Subathra D, Balasubramanian K, & Bernaitis L. (2024). Tuberculosis: New Challenges in Diagnosis and Treatment. In Global Journal of Research in Medical Sciences (Vol. 4, Number 6, pp. 13–17). https://doi.org/10.5281/zenodo.14046694